Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Read Report Overview @ https://www.transparencymarketresearch.com/pulmonary-drugs-market.html
Despite the projected decline, the demand for pulmonary drugs will continue to build as the population is reeling under the high prevalence of chronic respiratory disorders. The Forum of International Respiratory Societies (FIRS) states that the about 200 million meet their fatal end due to chronic obstructive pulmonary disease (COPD) and about 235 million due to asthma. These statistics have been the primary growth drivers for the overall pulmonary drugs market in the past few years. The rising number of smokers across the globe have also triggered the demand for pulmonary drugs as they are usually at the receiving end of respiratory disorders. The World Health Organization states that consumption of tobacco leads to six million deaths every year while 600, 000 are exposed to second-hand smoke, which is known to cause asthma. Thus the changes in lifestyle are anticipated to play a crucial role in the development of global market.
The global pulmonary drugs market is also benefitting from the increasing disposable incomes and the rising awareness about treating pulmonary ailments. The increasing investments made in research and development of pulmonary drug delivery systems have also favored market growth in recent times. The growing pool of unmet demands due to population explosion in several developing countries and the entry of innovative and effective drugs in the market is also anticipated to boost the uptake of these drugs in the coming few years.
Analysts anticipate that the negative growth of the global pulmonary drugs market will be attributable to the patent cliffs in the coming years that will hamper the revenues of several leading players. This issue will be further addled by the entry of generic drugs in the global market. The strict regulatory process of getting these drugs approved from various authorities is also expected to dampen the spirit of the market during the forecast period. Furthermore, the wide availability of counterfeit drugs is also acting a significant impediment to the overall market.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16751
The intensity of competition in the global pulmonary drugs market is exceptionally high with the presence of few dominant players. However, Transparency Market Research observes that the leading players are expected to lose their share in the overall market as patents for several drugs are poised to expire in the coming years. The top five players in the market are GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Astra Zeneca, Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc. “The companies will focus on building their pipelines and developing effective and result-oriented medicines to meet the unmet demands of the patients across the globe,” states the lead author of the research report.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024 here
News-ID: 831098 • Views: 549
More Releases from TMR - Research Reports
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment
Allergy Diagnostics Market is Projected to be Worth US$ 3.8 Billion by 2024
The opportunity presented by the global market was pegged at US$1.3 bn in 2015 and is projected to be worth US$3.8 bn by 2024, expanding at a strong CAGR of 12.8% therein. The consumables segment accounted for the major share in the allergy diagnostics market. The segment is projected to present a 50.1% share by 2024, registering the highest CAGR of 13.6% during the forecast period. The instruments segment, on the
More Releases for Analysts
Knightsbridge Advisors AG – The Role of Financial Analysts
Financial analysts are considered the “think tanks” of every asset management company along with the asset managers. They research and write reports on different types of investments and different financial conditions which are essential in decision making. Reports are used not only by asset managers but also by the clients, to enable them to come up with informed decisions regarding their investment undertaking. Aside from our pool
AAA supports analysts readjustment of commodities ratings
Boston, MA, USA (August 19, 2011) -- Alternative Asset Analysis has announced its support for Bank of America Merrill Lynch's readjustment of its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset. Alternative Asset Analysis (AAA), a research organization that advocates alternative investments, agrees with the approach from BofA Merrill Lynch Global Commodity Research team, adding that gold is retaining
AAA Supports Analysts' Readjustment of Commodities Ratings
Bank of America Merrill Lynch has readjusted its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset. Boston, MA, August 13, 2011 -- Bank of America Merrill Lynch has readjusted its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset. Alternative Asset Analysis (AAA), a research organization that advocates alternative
New Certification for Business Analysts launched
The International Business Analysis Qualifications Board (IBAQB) has launched a new certification for Business Analysts. The new IBAQB Certified Business Analyst certification is designed for people involved in analyzing business processes within an organization, modeling businesses and process improvement: Business Analysts, Process and Product Owners, Innovators, Product Designers, Process Optimization Professionals etc. The scheme was developed in cooperation between several international experts. The content of this scheme can therefore be seen
Carson Witter Appoints Metal and Energy Analysts
Brendon Oliver will be joining Carson Witter as a Metals Analyst in March 2011. Brendon is joining Carson Witter from UBS in London where he was a Metals Analyst since 2007. He previously worked at Lloyds Bank for 12 years and has over 16 years experience in this industry. Simon Bartlett will be joining Carson Witter as an Energy Analyst in April 2011. Simon is joining from the Trading
TOF Group Appoints Metal and Energy Analysts
Trinity Options and Futures Group (TOF Group) appoint Metal and Energy Analysts to support its Commodities Team. Robert Hoyte will be joining TOF Group as a Metals Analyst in September 2010. Robert is joining TOF Group from UBS in London where he was a Metals Analyst since 2006. He previously worked at Lloyds Bank for 12 years and has over 16 years experience in this industry. Nigel